






























































RESEARCH METHODS AND REPORTING
the bmj | BMJ 2021;372:n265 | doi: 10.1136/bmj.n265 1
Preferred reporting items for journal and conference  abstracts 
of systematic reviews and meta-analyses of diagnostic test 
 accuracy studies (PRISMA-DTA for Abstracts): checklist, 
 explanation, and elaboration 
Jérémie F Cohen,1 Jonathan J Deeks,2,3 Lotty Hooft,4 Jean-Paul Salameh,5,6 Daniël A Korevaar,7 
Constantine Gatsonis,8 Sally Hopewell,9 Harriet A Hunt,10 Chris J Hyde,10 Mariska M Leeflang,11 
Petra Macaskill,12 Trevor A McGrath,13 David Moher,14 Johannes B Reitsma,4 Anne W S Rutjes,15 
Yemisi Takwoingi,2,3 Marcello Tonelli,16 Penny Whiting,17 Brian H Willis,18 Brett Thombs,19 
 Patrick M Bossuyt,11 Matthew D F McInnes20
For many users of the biomedical 
literature, abstracts may be the only 
source of information about a study. 
Hence, abstracts should allow readers 
to evaluate the objectives, key design 
features, and main results of the study. 
Several evaluations have shown 
deficiencies in the reporting of journal 
and conference abstracts across study 
designs and research fields, including 
systematic reviews of diagnostic test 
accuracy studies. Incomplete reporting 
compromises the value of research to 
key stakeholders. The authors of this 
article have developed a 12 item 
checklist of preferred reporting items 
for journal and conference abstracts of 
systematic reviews and meta-analyses 
of diagnostic test accuracy studies 
(PRISMA-DTA for Abstracts). This article 
presents the checklist, examples of 
complete reporting, and explanations 
for each item of PRISMA-DTA for 
Abstracts.
The abstract is often the only section read by users 
of biomedical articles.1 On the basis of the abstract, 
many readers decide whether they will read the full 
text. The abstract is also critical to people who do 
not have access to the full text, owing to pay walls 
or because the article is written in a language they 
do not understand. Therefore, abstracts should 
enable a quick assessment of the study’s objectives, 
purpose, and key design features; present an 
accurate picture of the validity of the main results; 
and allow readers to evaluate whether the study can 
meet their information needs.2 Informative abstracts 
are also key to enabling effective literature searches 
in electronic databases, notably in the context of 
systematic reviews.
Several evaluations have shown deficiencies in the 
reporting of journal and conference abstracts across 
study designs and research fields.3-6 The PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement was developed to improve 
the reporting of systematic reviews, primarily for 
reviews of interventions.7 PRISMA for Abstracts is a 
checklist for reporting abstracts of systematic reviews.8
Because of the specific methods, terminology, and 
reporting requirements of diagnostic test accuracy 
(DTA) studies (table 1), our group developed the 
PRISMA-DTA checklist, which also includes guidance 
on abstracts.9 10 PRISMA-DTA for Abstracts includes 
12 essential items to report in journal and conference 
abstracts (table 2). A recent evaluation, however, 
found that only half of these items were consistently 
reported.11 This explanation and elaboration 
document gives examples of complete reporting and 
explanations for each item of the PRISMA-DTA for 
Abstracts checklist and is intended to provide a useful 
resource for authors of DTA reviews.
Methods for developing explanation and elaboration 
document
During the consensus meeting to develop the PRISMA-
DTA checklist,12 a first version of PRISMA-DTA for 
Abstracts was drafted, based on PRISMA for Abstracts 
and the PRISMA-DTA checklist.8 9 Compared with 
PRISMA for Abstracts, one item was deleted (item 8), 
and one new item was added (A1, about synthesis 
of results). We then circulated the draft PRISMA-DTA 
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SUMMARY POINTS
The PRISMA-DTA statement has become an internationally accepted reporting 
guideline for systematic reviews of diagnostic test accuracy studies
PRISMA-DTA for Abstracts is intended to improve the completeness and 
informativeness of journal and conference abstracts of systematic reviews of 
diagnostic test accuracy studies
PRISMA-DTA for Abstracts includes 12 essential items to report in journal and 
conference abstracts
This article provides the checklist, examples of complete reporting and 
explanations for each item of the checklist, and abstracts of two reviews that 
authors can use as examples for their abstracts
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for Abstracts checklist among PRISMA-DTA Group 
members for review and approval.
A writing committee (JFC, JJD, LH) drafted this 
explanation and elaboration document, which was 
then reviewed, edited, and approved by consensus by 
PRISMA-DTA Group members. Consistent with other 
reporting guidelines,8 13 14 we provide examples of 
complete reporting for each item and explanations 
clarifying the rationale for the item and how to 
incorporate it in the abstract. We have edited the 
examples by spelling out abbreviations. We also 
present the abstracts of two reviews that comply with 
the checklist in fewer than 300 words (box 1 and box 
2).
PRISMA-DTA for abstracts checklist, section 1: title and 
purpose
Item 1: Title
Identify the report as a systematic review (+/− meta-
analysis) of DTA studies.
Examples
1a: “Diagnostic accuracy of segmental enhancement 
inversion for diagnosis of renal oncocytoma at biphasic 
contrast-enhanced computed tomography: systematic 
review.”15
1b: “The diagnostic accuracy of serological tests for 
Lyme borreliosis in Europe: a systematic review and 
meta-analysis.”16
Explanation
To facilitate identification, the title should describe 
the article as a “systematic review” and as a “meta-
analysis” (examples 1a-b), if appropriate. To clarify 
the focus of the review, the title should contain 
the terms “diagnostic” and “accuracy,” thereby 
differentiating it from other aspects of test evaluation, 
such as reproducibility, prognostic accuracy, optimal 
threshold estimation, analytical performance, clinical 
utility, or cost effectiveness. Alternatively, terms 
that refer to diagnostic accuracy measures (such as 
sensitivity, specificity, predictive values, or area under 
the curve) may be used. The title should also contain 
the index test, the target condition, and comparisons 
made between tests, if applicable. Incorporating a 
description of participants is encouraged.
Item 2: Objectives
Indicate the research question, including components 
such as participants, index test, and target conditions.
Examples
2a: “To assess the diagnostic accuracy of Xpert® MTB/
RIF for pulmonary tuberculosis detection, where 
Xpert® MTB/RIF was used as both an initial test 
replacing microscopy and an add-on test following a 
negative smear microscopy result.”17
2b: “To assess the diagnostic accuracy of magnetic 
resonance imaging for differentiating stage T1 or lower 
tumors from stage T2 or higher tumors and to analyse 
the influence of different imaging protocols in patients 
with bladder cancer.”18
Explanation
Abstracts should include the research question for 
the systematic review so that readers can understand 
the rationale and relevance for clinical practice. This 
should reflect the target condition(s) for detection 
(example 2a) or differentiation (example 2b), 
index test(s) under evaluation (examples 2a-b), the 
population for intended use (example 2b), the setting, 
and the proposed role of the index test(s) (example 
2a). Authors may also highlight comparative review 
questions here.
PRISMA-DTA for abstracts checklist, section 2: methods
Item 3: Eligibility criteria
Include the study characteristics used as criteria for 
eligibility.
Examples
3a: “We included randomised controlled trials, 
cross-sectional studies, and cohort studies using 
respiratory specimens that allowed for extraction of 
data evaluating Xpert® MTB/RIF against the reference 
standard. We excluded gastric fluid specimens. The 
reference standard for tuberculosis was culture and for 
rifampicin resistance was phenotypic culture-based 
drug susceptibility testing.”17
3b: “We included diagnostic accuracy studies that 
used computed tomography for diagnosis of fat-poor 
angiomyolipoma in patients with renal masses, using 
pathologic examination as the reference standard.”19
Table 1 | Diagnostic test accuracy terminology
Term Explanation
Index test Test under evaluation in a diagnostic accuracy study. The accuracy (eg, sensitivity and specificity) of the index test is estimated by comparing the 
results of the index test with those of a reference standard applied to the same participants. Multiple index tests can be evaluated within the same 
study
Comparative studies Studies aiming to compare the diagnostic accuracy of two or more index tests
Reference standard The method or combination of methods used in the study for establishing the presence or absence of the target condition
Target condition The disease or condition that the reference standard is expected to detect
Role of the test The position of the index test relative to other tests in the diagnostic investigation of the same target condition (eg, triage, replacement, add-on, new 
test)
Intended use of the test Whether the index test is used for diagnosis, screening, staging, monitoring, surveillance, prognosis, or other purposes
Sensitivity The proportion of correctly classified participants among those with the target condition
Specificity The proportion of correctly classified participants among those without the target condition
QUADAS-2 A tool for use in systematic reviews to assess the risk of bias and concerns about applicability of primary diagnostic accuracy studies
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Explanation
A clear description of the systematic review’s eligibility 
criteria allows readers to judge the applicability 
of findings. Eligibility criteria should include all 
components of the review question (item 2) plus 
the reference standard (examples 3a-b), along with 
any restrictions on study design, such as excluding 
studies with healthy controls. In comparative reviews, 
the authors may restrict studies to those in which 
participants underwent all tests under comparison. 
Additional examples of eligibility criteria may include 
year of publication, language, or publication status (for 
example, no conference abstracts). Results from older 
studies sometimes differ from more recent results, and 
studies published in non-English language journals or 
only in conference abstracts may report lower accuracy 
estimates.20-24
Item 4: Information sources
List the key databases searched and the search dates.
Examples
4a: “A systematic search of MEDLINE, Embase, The 
Cochrane Library and Science Citation Index Expanded 
from January 1994 to October 2014 was performed.”25
4b: “We carried out extensive literature searches 
including MEDLINE (1980 to 25 August 2011), Embase 
(1980 to 25 August 2011), BIOSIS via EDINA (1985 to 
Table 2 | PRISMA-DTA for Abstracts checklist
Section and topic Item No Description
Title and purpose
Title 1 Identify the report as a systematic review (+/– meta-analysis) of DTA studies
Objectives 2 Indicate the research question, including components such as participants, index test, and target conditions
Methods
Eligibility criteria 3 Include study characteristics used as criteria for eligibility
Information sources 4 List the key databases searched and the search dates
Risk of bias and 
applicability
5 Indicate the methods of assessing risk of bias and applicability
Synthesis of results A1 Indicate the methods for the data synthesis
Results
Included studies 6 Indicate the number and type of included studies and the participants and relevant characteristics of the studies (including the reference 
standard)
Synthesis of results 7 Include the results for the analysis of diagnostic accuracy, preferably indicating the number of studies and participants. Describe test 
accuracy including variability; if meta-analysis was done, include summary results and confidence intervals
Discussion
Strengths and limitations 9 Provide a brief summary of the strengths and limitations of the evidence
Interpretation 10 Provide a general interpretation of the results and the important implications
Other
Funding 11 Indicate the primary source of funding for the review
Registration 12 Provide the registration number and the registry name
Compared with PRISMA for Abstracts, one item was deleted (item 8), and one new item was added (A1).
DTA=diagnostic test accuracy.
Box 1: Example of abstract fulfilling all PRISMA-DTA for Abstracts items in less than 250 words
Diagnostic accuracy of dual-energy computed tomography (DECT) to differentiate uric acid from non-uric acid calculi: systematic review and meta-
analysis
Background: Uric acid stone diagnosis is done primarily with in vitro analysis of stones. Dual-energy CT (DECT) would allow earlier diagnosis and 
therapy.
Objective: To evaluate if DECT, using stone analysis as reference standard, is sufficiently accurate to replace stone analysis for diagnosis of uric acid 
stones.
Methods: Original studies in patients with urolithiasis examined with DECT with stone analysis as the reference standard were eligible for inclusion. 
MEDLINE (1946–2018), Embase (1947–2018), CENTRAL (August 2018), and multiple urology and radiology conferences were searched. QUADAS-2 
was used to assess risk of bias and concerns regarding applicability. Meta-analyses were performed using a bivariate random-effects model.
Results: Twenty-one studies (1105 patients, 1442 stones) were included. Fourteen studies (662 patients, 944 stones) were analyzed in the uric acid 
dominant target condition (majority of stone composition uric acid): summary sensitivity was 0.88 (95% CI 0.79–0.93) and specificity 0.98 (95% CI 
0.96–0.99). Thirteen studies (674 patients, 760 stones) were analyzed in the uric acid-containing target condition (< majority of stone composition 
uric acid): summary sensitivity was 0.82 (95% CI 0.73–0.89) and specificity 0.97 (95% CI 0.94–0.98). Meta-regression identified no significant 
source of variability in accuracy. Two studies had one or more domains at high risk of bias and there were no concerns regarding applicability.
Conclusion: DECT is an accurate replacement test for diagnosis of uric acid calculi in vivo, such that stone analysis might be replaced in the diagnostic 
pathway.
Funding: Ontario Graduate Scholarship (OGS).
Registration: CRD42018107398 (Prospero).
Word count: 249.
Adapted with permission of authors from McGrath TA et al. Eur Radiol 2020;30:2791-01.
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25 August 2011), CINAHL via OVID (1982 to 25 August 
2011), and The Database of Abstracts of Reviews of 
Effects (the Cochrane Library 2011, Issue 7).”26
Explanation
The abstract should report the databases searched 
with the date range or date of last search. This informs 
readers of the completeness and recency of the search 
and the likelihood that potentially relevant articles 
have been missed. Additional efforts made to identify 
studies (for example, searching reference lists of 
included studies and published reviews, contacting 
experts, screening trial registries) are often not 
reported in the abstract because of word restrictions.
Item 5: Risk of bias and applicability
Indicate the methods of assessing risk of bias and 
applicability.
Example
5a: “We assessed possible bias and applicability of the 
studies using the QUADAS-2 tool.”27
Explanation
Aspects of the design and conduct of included primary 
DTA studies can raise questions about the validity of 
their findings and applicability for the review question. 
These include aspects that increase “risk of bias” (that 
is, estimates that deviate systematically from the truth) 
and aspects that lead to “concerns about applicability” 
(that is, study results that do not directly apply to the 
review question). Non-blinded readers of index tests, 
for example, can introduce bias.28 29 Recruiting a highly 
selected study group or using a prototype version of a 
test may affect applicability. Systematic reviews should 
evaluate risk of bias and concerns about applicability; 
review authors may not be able to describe this in detail 
in the abstract but can specify the tool or approach 
used. The QUADAS-2 tool 30 (example 5a) is the most 
frequently used tool for DTA studies.31
Item A1: Synthesis of results
Indicate the methods for the data synthesis.
Examples
A1a: “We performed meta-analyses using the 
bivariate and hierarchical summary receiver operating 
characteristic models.”32
A1b: “Variability was assessed by subgroup analyses 
(dual-energy computed tomography technique and 
risk of bias) and metaregression using test type and 
threshold applied as covariates.”33
A1c: “We analysed sensitivity and specificity of 
included studies narratively as there were insufficient 
studies to perform a meta-analysis.”34
Explanation
Authors are encouraged to report the approach taken 
to summarise study results, whether narratively 
or using a statistical model. Results from different 
approaches may diverge,35 36 and some strategies are 
more robust than others. Example A1a informs readers 
about key details of the analysis, such as whether 
statistical methods account for the hierarchical nature 
of data and the potential trade-off between sensitivity 
and specificity across studies. How authors evaluated 
variability in accuracy estimates may also be relevant 
(example A1b). If applicable, we encourage authors 
Box 2: Example of abstract fulfilling all PRISMA-DTA for Abstracts items in less than 300 words
Rapid antigen detection tests for group A streptococcus in children with pharyngitis: systematic review and meta-analysis of diagnostic test accuracy 
studies
Background: Group A streptococcus (GAS) accounts for 20% to 40% of cases of pharyngitis in children; the remaining cases are caused by viruses. 
Compared with throat culture, rapid antigen detection tests (RADTs) offer diagnosis at the point of care.
Objectives: To evaluate the diagnostic accuracy of RADTs for diagnosing GAS in children with pharyngitis.
Methods: We searched 8 databases (including MEDLINE and Embase) from 1980 through 2015. We included studies that compared RADT for GAS 
pharyngitis with throat culture on a blood agar plate in a microbiology laboratory in children in ambulatory care. Quality assessment was carried out 
using QUADAS-2. We used bivariate meta-analysis to estimate summary sensitivity and specificity, and to investigate variability in accuracy across 
studies.
Results: We included 98 unique studies in the review (116 test evaluations; 101 121 participants). The overall methodological quality of included 
studies was poor, mainly because many studies were at high risk of bias regarding patient selection and the reference standard used. In our main 
meta-analysis (105 test evaluations; 58 244 participants; median prevalence of GAS 29.5%), RADT had a summary sensitivity of 85.6% (95% CI 
83.3 to 87.6) and a summary specificity of 95.4% (95% CI 94.5 to 96.2). There was substantial variability in sensitivity across studies (range 38.6 
to 100%); specificity was more stable (range 54.1 to 100%). Variability in accuracy was not explained by study-level characteristics such as age and 
clinical severity of participants, and GAS prevalence.
Conclusions: Whether or not RADT can be used as a stand-alone test to rule out GAS will depend mainly on the epidemiological context. RADT 
specificity seems sufficiently high to ensure against unnecessary use of antibiotics. These results should be interpreted with caution because of high 
risk of bias and variability in sensitivity estimates.
Funding: Association Française de Pédiatrie Ambulatoire (AFPA).
Registration: CD010502 (Cochrane).
Word count: 299.
Adapted with permission of authors from Cohen JF et al. Cochrane Database Syst Rev 2016(7):CD010502.
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to report methods used for comparisons of multiple 
index tests and reasons for not pooling study results 
(example A1c).
PRISMA-DTA for abstracts checklist, section 3: results
Item 6: Included studies
Indicate the number and type of included studies and 
the participants and relevant characteristics of the 
studies (including the reference standard).
Examples
6a: “We included 27 unique studies […] involving 9557 
participants. Sixteen studies (59%) were performed in 
low- or middle-income countries.”17
6b: “For the diagnostic accuracy of HBsAg from 
dried blood spot compared to venous blood, 19 studies 
were included in a quantitative meta-analysis, and 23 
in a narrative review.”37
6c: “Of the 40 studies that met the inclusion criteria, 
33 compared rapid diagnostic test and/or enzyme 
immunoassays against enzyme immunoassays and 
7 against nucleic-acid test as reference standards. 
Thirty studies assessed diagnostic accuracy of 33 
brands of rapid diagnostic tests in 23,716 individuals 
from 23 countries using enzyme immunoassays as the 
reference standard.”38
6d: “All studies were at high risk of bias for the index 
test domain because no reported thresholds were 
prespecified.”39
Explanation
Authors should report the number of included studies 
and participants (and, if possible, the number of 
participants with the target condition) and any other 
key characteristics (example 6a). Some studies may 
be included in the qualitative part of the review but 
not in the quantitative synthesis (example 6b). If the 
included studies use multiple reference standards, 
this should be reported (example 6c). This information 
enables readers to gauge the amount of summarised 
evidence and its applicability to the review question. 
Reviews with few included studies and a limited 
number of participants may produce imprecise 
accuracy estimates and may not add substantive value 
compared with the individual studies. Review authors 
are also invited to summarise their assessment of the 
quality of evidence (that is, risk of bias and concerns 
about applicability) and highlight their main source of 
concern (example 6d).
Item 7: Synthesis of results
Include the results for the analysis of diagnostic 
accuracy, preferably indicating the number of studies 
and participants. Describe test accuracy including 
variability; if meta-analysis was done, include 
summary results and confidence intervals.
Examples
7a: “In the 12 studies with the least biased estimates, 
sensitivity ranged from 30% to 87% and specificity 
ranged from 86% to 100%.”40
7b: “As an initial test replacing smear microscopy, 
Xpert® MTB/RIF pooled sensitivity was 89% [95% 
Credible Interval (CrI) 85% to 92%] and pooled 
specificity 99% (95% CrI 98% to 99%), (22 studies, 
8998 participants: 2953 confirmed tuberculosis, 
6045 non-tuberculosis). As an add-on test following 
a negative smear microscopy result, Xpert®MTB/RIF 
pooled sensitivity was 67% (95% CrI 60% to 74%) 
and pooled specificity 99% (95% CrI 98% to 99%; 21 
studies, 6950 participants).”17
7c: “For HRP-2, the meta-analytical average 
sensitivity and specificity (95% CI) were 95.0% (93.5% 
to 96.2%) and 95.2% (93.4% to 99.4%), respectively 
[…], for pLDH, the meta-analytical average sensitivity 
and specificity (95% CI) were 93.2% (88.0% to 96.2%) 
and 98.5% (96.7% to 99.4%), respectively.”41
7d: “Compared to microscopy, the detection of 
microhaematuria on test strips had the highest 
sensitivity and specificity (sensitivity 75%, 95% CI 
71% to 79%; specificity 87%, 95% CI 84% to 90%; 
74 studies, 102,447 participants). For proteinuria, 
sensitivity was 61% and specificity was 82% (82,113 
participants); and for leukocyturia, sensitivity was 
58% and specificity 61% (1,532 participants). 
However, the difference in overall test accuracy 
between the urine reagent strips for microhaematuria 
and proteinuria was not found to be different when we 
compared separate populations (P = 0.25), or when 
direct comparisons within the same individuals were 
performed (paired studies; P = 0.21).”42
Explanation
The authors should provide results for the main index 
test(s) evaluated in the abstract and, if relevant, 
thresholds defining index test positivity. If no meta-
analysis was done, the abstract should describe 
accuracy results across included studies—for example, 
by describing the range of estimates (example 7a). 
If meta-analysis was done, authors should include 
summary estimates of accuracy and an expression of 
statistical imprecision, such as confidence intervals, 
prediction intervals, or Bayesian credible intervals 
(examples 7b-d). If space allows, authors should 
report the number of studies and participants used 
to generate summary estimates for each index test 
(example 7b and 7d).
Measures of statistical inconsistency 
(“heterogeneity”) used in intervention reviews (such 
as I2) are usually not applicable in systematic reviews 
of DTA studies, and no consensus exists for alternative 
statistics. As such, the broader term “variability” 
was used in place of the term “inconsistency” in 
PRISMA-DTA. Variability of accuracy results could be 
mentioned in the abstract and may include results of 
main investigations of reasons for variability, such 
as subgroup analyses and meta-regression (example 
7d).43
If the review aimed to compare tests, these results 
should be reported, preferably including relative or 
absolute differences in accuracy, with confidence 
intervals or tests for statistical significance (example 
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7d). If sensitivity analysis raised serious concerns 
about the robustness of the main analyses, this should 
be mentioned as well.
PRISMA-DTA for abstracts checklist, section 4: 
discussion
Item 9: Strengths and limitations
Provide a brief summary of the strengths and 
limitations of the evidence.
Examples
9a: “The spectrum of patients was relatively narrow 
in all studies, sample sizes were small, there 
was substantial incorporation bias, and blinding 
procedures were often incomplete.”44
9b: “The value of accuracy estimates is considerably 
undermined by the small number of included studies, 
and concerns about risk of bias relating to the index 
test and the reference standard.”34
9c: “We observed substantial variation in sensitivity 
and specificity of all tests, which was likely attributable 
to methodological differences and variations in the 
clinical characteristics of populations recruited.”45
Explanation
The abstract should briefly highlight the main 
strengths and limitations of the review process and the 
included evidence. Review limitations might include 
search restrictions (for example, number of databases, 
language, dates) and lack of independent study 
selection and data extraction by more than one person, 
for example. Limitations of included evidence might 
include risk of bias (examples 9a-b), unavailability of 
data (examples 9a-b), variability of accuracy estimates 
(example 9c), imprecision (for example, due to few 
studies or small sample sizes; examples 9a-b), or low 
applicability of study findings (for example, due to 
patient selection within the included studies; example 
9a). Such limitations may lead to summary estimates 
of accuracy that may not reflect the “true” performance 
of a test or may limit applicability in real world clinical 
use. Reporting all limitations in an abstract might be 
impossible, but the authors should mention those that 
they deem most important.
Item 10: Interpretation
Provide a general interpretation of the results and the 
important implications.
Examples
10a: “Compared with microscopy, Xpert offers better 
sensitivity for the diagnosis of pulmonary tuberculosis 
in children and its scale-up will improve access 
to tuberculosis diagnostics for children. Although 
Xpert helps to provide rapid confirmation of disease, 
its sensitivity remains suboptimum compared with 
culture tests. A negative Xpert result does not rule out 
tuberculosis. Good clinical acumen is still needed to 
decide when to start antituberculosis therapy and 
continued research for better diagnostics is crucial.”46
10b: “It might be too early to recommend its use 
because of the scarcity of reliable clinical data, 
heterogeneity in case definitions, and unstable 
accuracy estimates.”47
10c: “If the point estimates for Type 1 and Type 
4 tests are applied to a hypothetical cohort of 
1000 patients where 30% of those presenting with 
symptoms have P. falciparum, Type 1 tests will miss 16 
malaria cases, and Type 4 tests will miss 26 malaria 
cases. The number of people wrongly diagnosed with 
P. falciparum malaria would be 34 with Type 1 tests, 
and nine with Type 4 tests.”41
Explanation
“Spin,” which refers to the reporting of findings in a 
way that makes test performance seem better than is 
justified by the study results, is common in abstracts of 
DTA systematic reviews.48 49 The abstract’s conclusion 
should summarise the evidence with wording that 
reflects potential limitations of the review and evidence 
and, ideally, account for the intended use of the test 
(example 10a; table 1). If insufficient evidence from 
well conducted studies exists to allow conclusions to 
be drawn, this should be made clear (example 10b). 
If the word count permits, providing readers with 
the numbers of patients who would be expected to 
obtain correct and erroneous test results, and the 
likely consequences, may help with interpretation of 
test accuracy results and differences between tests 
(example 10c).
PRISMA-DTA for abstracts checklist, section 5: other
Item 11: Funding
Indicate the primary source of funding for the review.
Examples
11a: “Primary funding source: Québec Health Research 
Fund and BD Diagnostic Systems.”50
11b: “Funding: No external funding.”51
Explanation
A conference abstract should include the main funding 
source(s) of the review (example 11a) or state that there 
was no specific funding (example 11b). Journals may 
require this to be reported elsewhere. This information 
enables readers to assess whether financial conflicts of 
interest occurred if, for instance, the test manufacturer 
provided funding for the review. Other financial 
conflicts of interest, such as when the inventors of 
a test are involved in the review,52 are relevant but 
not easily conveyed in the abstract. Ideally, whether 
financial support came from a for-profit company or a 
public funder should be made clear.
Item 12: Registration
Provide the registration number and the registry name.
Example
12a: “This study was registered with PROSPERO 
(CRD42018089545).”47
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Explanation
Registration of systematic reviews is increasingly 
expected.53 54 Registration provides evidence that a 
review is being undertaken prospectively and provides 
a record of reviews that have been initiated, which 
reduces the risk of duplicated efforts and allows 
interested parties to contact reviewers. It also enables 
peer reviewers, editors, and readers to compare 
reported review methods against the registered 
record.55 As registries such as PROSPERO are typically 
open access, including the number and name of 
the registry may provide a useful additional source 
of information. Alternatives to citing an entry on a 
register include providing a link to an upload of the 
review protocol on a publicly available website (such 
as the Open Science Framework), preprint server (such 
as medRxiv.org), or journal publication (with the DOI).
Discussion
We developed the PRISMA-DTA for Abstracts checklist 
and have provided this explanation and elaboration 
document to help authors to improve the reporting 
of journal and conference abstracts of systematic 
reviews of DTA studies. This explanation and 
elaboration document is a companion to the checklist 
and the explanation and elaboration for PRISMA-
DTA for full text reviews.9 10 It may also be useful as 
a pedagogical resource for people learning about DTA 
systematic review abstracts. PRISMA-DTA for Abstracts 
enriches the body of reporting guidelines for journal 
and conference abstracts,2 including CONSORT for 
Abstracts of randomised trials of interventions,56 
PRISMA for Abstracts of systematic reviews,8 STROBE 
for Abstracts of observational studies,57 STARD for 
Abstracts of primary DTA studies,58 PRIO for Abstracts 
of overviews of systematic reviews,59 and TRIPOD for 
Abstracts of multivariable prediction models.60 In 
addition to supporting authors, these checklists can 
be used by editors, peer reviewers, and conference 
organisers to assess the completeness of abstracts 
submitted for publication or presentation. We also 
provided illustrative examples of real abstracts that 
comply with the checklist (box 1 and box 2).
An evaluation of adherence to the PRISMA-DTA 
for Abstracts checklist, based on 100 published 
DTA reviews (2017-2018), found abstracts to be 
insufficiently informative.11 Items reported in less 
than 50% of abstracts included items 2 (participants: 
49%), 4 (search dates: 42%), 5 (methods for assessing 
risk of bias: 38%; methods for assessing applicability: 
25%), 6 (characteristics of included studies 
(including reference standard): 13%), 9 (strengths: 
8%; limitations: 26%), 11 (funding: 3%), and 12 
(registration: 5%).
To ensure that abstracts of systematic reviews of 
DTA studies are sufficiently informative, we strongly 
recommend the use of structured abstracts.61 62 
Recognising that many journals and conferences 
have their own abstract formatting requirements, 
we indicate the information that should be reported 
without specifying abstract sections. Authors should 
mention key features only once to make the best use 
of the limited space available. We encourage journals 
and organisers of scientific conferences to endorse the 
use of PRISMA-DTA for Abstracts. This may be done by 
implementing the checklist into instructions to authors 
and by inviting peer reviewers to use it when evaluating 
study reports. The usual 250 word limit used by many 
journals and conferences may be a barrier to complete 
reporting. We invite journal editors and conference 
organisers to consider increasing their word limit to at 
least 300 words. For example, Radiology and The BMJ 
now allow abstracts up to 300 and 400 words long, 
respectively.
To enhance dissemination, all PRISMA-DTA for 
Abstracts material will be freely available on the 
EQUATOR (www.equator-network.org) and PRISMA 
(www.prisma-statement.org) websites. We also 
encourage the introduction of PRISMA-DTA and 
PRISMA-DTA for Abstracts in teaching programmes 
focusing on systematic reviews of DTA studies and the 
importance of transparent reporting of health research.
PRISMA-DTA for Abstracts presents a minimum set 
of reporting criteria that should be reported in abstracts 
of systematic reviews of DTA studies. When possible, 
authors should also report other items from the full 
PRISMA-DTA checklist in the abstract,9 especially 
those deemed critical to their review question. For 
conferences that allow the inclusion of figures in the 
abstract, a chart describing the flow of study inclusion 
through the review is also welcomed. Other figures may 
include key forest and summary receiver operating 
characteristics plots or a test consequence graphic.63
The checklist aims at ensuring complete reporting, 
but it cannot guarantee that reviews adhere to 
principles of good research practice and research 
integrity. Guidance for appropriate methods to conduct 
systematic reviews of DTA studies can be found 
elsewhere (for example, the Cochrane Handbook for 
Systematic Reviews of Diagnostic Test Accuracy).64 The 
abstract should be a fair and honest summary of the full 
study report. As in the full text, distorted and selective 
reporting of findings (“spin”) should be avoided.48 49 
Clinical implications should be justified by the results, 
and an accurate description of limitations should be 
provided.
Abstracts are not a replacement for full text articles 
in informing clinical practice, policy decisions, or other 
research. However, they must present an accurate and 
trustworthy account of the research conducted and 
reported. The PRISMA-DTA for Abstracts checklist can 
guide authors in preparing an informative, complete, 
and fair summary of their review, thus increasing 
the value of the abstract to the clinical and scientific 
community.65 For full reports of systematic reviews 
of DTA studies, authors are encouraged to use the 
PRISMA-DTA checklist.9 10
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